Sign in with your email address username.


[Correspondence] Immunosuppression for management of Crohn’s disease

We read with interest the study by Reena Khanna and colleagues1 describing early combined immunosuppression (ECI) for the management of Crohn’s disease (REACT trial). The authors aimed to compare the effectiveness of ECI treatment (an anti-TNF drug with antimetabolite treatment) with a conventional step-up approach in a real-life setting. The ECI was based on the results of the so-called top-down versus step-up trial2 and the SONIC trial.3 However, there are important differences in the patient population of the REACT trial compared with these two earlier studies.